Tempus AI stock has fallen 22.4% year to date, yet the valuation checks point to a mixed picture rather than a clear verdict on whether the recent weakness leaves the shares cheap or still demanding.

• After declining 22.4% year to date, Tempus AI is back under pressure. This puts more focus on whether the current price fairly reflects its prospects in healthcare AI and diagnostics.
• The planned all stock acquisition of Personalis for about US$1.5b can support expectations of a larger role in cancer monitoring. At the same time, the integration and execution risks around that deal may weigh on how investors price the stock.
• With Tempus AI screening as undervalued on market multiples but passing only 3 of 6 valuation checks, the broader assessment is a mixed picture rather than a straightforward bargain.

The issue now is whether Tempus AI’s current share price already reflects the growth investors expect from its oncology platform and recent acquisitions, or still offers a margin of safety.

Does Tempus AI Look Undervalued on Sales?

The P/S multiple is often a useful cross check for Tempus AI because revenue is a clearer reference point than earnings for a company that is still loss making. On this basis, Tempus AI trades at about 6.4x sales, compared with a Life Sciences industry average of roughly 3.9x and a peer group average of about 5.1x. At first glance, the stock therefore sits at a premium to the broader industry and a little above more direct peers.

However, the tailored fair P/S ratio for Tempus AI is estimated at about 7.9x, which is higher than the current 6.4x level. This suggests the stock screens as undervalued on this framework. Despite the all stock Personalis deal, which highlights that the market is willing to pay much higher sales multiples for key oncology and MRD assets, Tempus AI still trades below the P/S ratio implied by its own profile and risk balance.

On the preferred P/S multiple, Tempus AI stock currently appears undervalued relative to the fair ratio implied by its characteristics.

The Tempus AI Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Tempus AI sit on the Community page and act as a bridge from the mixed valuation signals to explicit scenarios. They spell out what kind of revenue growth, profitability and earnings path would need to play out for the stock to be worth materially more or less than today’s price. Each one ties its figure to a clear view on how Tempus AI's growth, margins and risk profile could evolve, giving you something concrete to revisit as new information emerges.

Community views on Tempus AI sit far apart, with one group focusing on its data moat and another on execution and cost risk.

Bull case: 27% undervalued

"This data moat is what makes the business interesting.…"

Bear case: 28% overvalued

"Large technology and healthcare players are pushing into AI driven clinical data and diagnostics, and if they secure comparable datasets or tighter distribution with providers, Tempus AI's current advantage in proprietary data and hospital connectivity could erode over time.…"

Do you think there's more to the story for Tempus AI? Head over to our Community to see what others are saying!

The Bottom Line

For Tempus AI, the valuation work points to a stock that screens as undervalued on its preferred P/S multiple, but with a broader set of checks that is only mixed rather than clearly supportive. That leaves the current discount looking more like a debate about risk than a simple mispricing. The key question from here is whether Tempus AI can execute on its oncology and acquisition plans well enough to justify a stronger multiple, or whether integration and cost pressures continue to explain why the market is hesitant to pay closer to the implied fair ratio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.